XML 24 R12.htm IDEA: XBRL DOCUMENT

DEPOSIT	12 Months Ended
Dec. 31, 2018
DEPOSIT [Text Block]	6. DEPOSIT On September 10, 2018, Live Current entered into a non-binding letter of intent (the “LOI”) with Cell MedX Corp. (Cell MedX) for worldwide distribution rights of the e-Balance device for home-based usage. The e-Balance device is a micro-current therapy device designed to target complications arising from diabetes, but has yet to receive approval from the Food and Drug Administration ("FDA"). Pursuant to the LOI, the Company agreed to enter into negotiations aimed at obtaining a definitive agreement within a 90 -day period (note 10). The Company advanced US$250,000 as a deposit for exclusive worldwide distribution rights. The probability of success and length of time to obtain Federal Drug Administration approval of the e-Balance device is difficult to determine and there are uncertainties associated with the timely completion of the device’s commercial success. Due to the uncertainties associated with the successful commercialization of the e-Balance device, it has been determined that the payment of this deposit does not meet the definition of an asset and is thus expensed within general and administrative expenses.

DEPOSIT

12 Months Ended

Dec. 31, 2018

6. DEPOSIT

On September 10, 2018, Live Current entered into a non-binding letter of intent (the “LOI”) with Cell MedX Corp. (Cell MedX) for worldwide distribution rights of the e-Balance device for home-based usage. The e-Balance device is a micro-current therapy device designed to target complications arising from diabetes, but has yet to receive approval from the Food and Drug Administration ("FDA"). Pursuant to the LOI, the Company agreed to enter into negotiations aimed at obtaining a definitive agreement within a 90 -day period (note 10). The Company advanced US$250,000 as a deposit for exclusive worldwide distribution rights. The probability of success and length of time to obtain Federal Drug Administration approval of the e-Balance device is difficult to determine and there are uncertainties associated with the timely completion of the device’s commercial success. Due to the uncertainties associated with the successful commercialization of the e-Balance device, it has been determined that the payment of this deposit does not meet the definition of an asset and is thus expensed within general and administrative expenses.